Trial Profile
Valdoxan ImproVes depRession with anxiEty symptoms: a non-interventional study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2013
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Acronyms VIVRE
- 31 Jan 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 22 Jun 2012 New trial record